 Clyde Wright
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 19 | 2022 | 326 | 7.590 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 100 | 7.490 |
Why?
| | NF-kappa B | 21 | 2024 | 634 | 7.020 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 100 | 6.160 |
Why?
| | Acetaminophen | 12 | 2023 | 240 | 6.090 |
Why?
| | Endotoxemia | 9 | 2023 | 84 | 5.820 |
Why?
| | I-kappa B Proteins | 12 | 2022 | 76 | 4.230 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 50 | 4.140 |
Why?
| | Ductus Arteriosus, Patent | 7 | 2023 | 50 | 3.780 |
Why?
| | Liver | 14 | 2023 | 1716 | 3.770 |
Why?
| | Lung Injury | 7 | 2022 | 191 | 3.510 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 91 | 2.990 |
Why?
| | Infant, Newborn | 43 | 2023 | 5060 | 2.930 |
Why?
| | Lung | 18 | 2022 | 3624 | 2.860 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 32 | 2.820 |
Why?
| | Immunity, Innate | 8 | 2023 | 733 | 2.290 |
Why?
| | Infant, Premature | 14 | 2023 | 472 | 2.110 |
Why?
| | Hyperoxia | 7 | 2017 | 89 | 2.080 |
Why?
| | Surface-Active Agents | 8 | 2023 | 79 | 1.890 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 111 | 1.860 |
Why?
| | Transcription Factor RelA | 3 | 2024 | 80 | 1.770 |
Why?
| | Signal Transduction | 16 | 2020 | 4537 | 1.730 |
Why?
| | Infant, Extremely Premature | 7 | 2023 | 58 | 1.650 |
Why?
| | Biological Products | 3 | 2021 | 172 | 1.590 |
Why?
| | Oxygen | 6 | 2022 | 818 | 1.540 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 287 | 1.480 |
Why?
| | Macrophages | 7 | 2020 | 1273 | 1.470 |
Why?
| | Lipopolysaccharides | 8 | 2023 | 822 | 1.410 |
Why?
| | Ibuprofen | 4 | 2023 | 73 | 1.390 |
Why?
| | Neonatology | 2 | 2021 | 18 | 1.340 |
Why?
| | Airway Extubation | 2 | 2020 | 45 | 1.260 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 25 | 1.240 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 680 | 1.240 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1126 | 1.150 |
Why?
| | Animals, Newborn | 11 | 2021 | 785 | 1.130 |
Why?
| | Animals | 34 | 2024 | 32091 | 1.080 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 104 | 1.070 |
Why?
| | Mice | 24 | 2024 | 15075 | 1.060 |
Why?
| | Humans | 66 | 2023 | 115297 | 1.000 |
Why?
| | Pregnancy | 11 | 2022 | 5540 | 0.970 |
Why?
| | Physician's Role | 2 | 2021 | 197 | 0.880 |
Why?
| | Apoptosis | 5 | 2017 | 2363 | 0.870 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2366 | 0.870 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 55 | 0.840 |
Why?
| | Premature Birth | 3 | 2022 | 273 | 0.830 |
Why?
| | Cytochrome P-450 CYP2E1 | 4 | 2023 | 38 | 0.790 |
Why?
| | Interleukin-1beta | 3 | 2020 | 367 | 0.790 |
Why?
| | Streptozocin | 1 | 2021 | 16 | 0.780 |
Why?
| | Disease Models, Animal | 10 | 2021 | 3565 | 0.780 |
Why?
| | Inflammation | 3 | 2020 | 2482 | 0.770 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 276 | 0.770 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.750 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2022 | 134 | 0.730 |
Why?
| | Oxidative Stress | 3 | 2017 | 1089 | 0.730 |
Why?
| | Toll-Like Receptor 9 | 1 | 2020 | 30 | 0.710 |
Why?
| | Monocytes | 1 | 2023 | 501 | 0.710 |
Why?
| | Ovarian Follicle | 1 | 2020 | 61 | 0.710 |
Why?
| | Fetal Growth Retardation | 2 | 2023 | 466 | 0.710 |
Why?
| | Chorioamnionitis | 1 | 2020 | 35 | 0.710 |
Why?
| | Acidosis | 1 | 2020 | 83 | 0.680 |
Why?
| | Oximetry | 2 | 2017 | 78 | 0.670 |
Why?
| | Uterus | 1 | 2020 | 193 | 0.660 |
Why?
| | Respiration, Artificial | 5 | 2022 | 522 | 0.640 |
Why?
| | Emphysema | 1 | 2019 | 124 | 0.640 |
Why?
| | Inflammation Mediators | 3 | 2019 | 475 | 0.630 |
Why?
| | Interferon-beta | 1 | 2018 | 80 | 0.630 |
Why?
| | Fetus | 4 | 2020 | 701 | 0.630 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 50 | 0.620 |
Why?
| | Calcium Signaling | 1 | 2020 | 211 | 0.620 |
Why?
| | Treatment Failure | 2 | 2019 | 331 | 0.610 |
Why?
| | Sugars | 1 | 2018 | 30 | 0.610 |
Why?
| | Beverages | 1 | 2018 | 59 | 0.600 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 5 | 0.590 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 315 | 0.580 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 241 | 0.570 |
Why?
| | Respiration | 2 | 2018 | 179 | 0.570 |
Why?
| | Peer Review, Research | 1 | 2017 | 34 | 0.570 |
Why?
| | Gene Expression | 3 | 2024 | 1451 | 0.570 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 174 | 0.570 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 74 | 0.560 |
Why?
| | Standard of Care | 1 | 2017 | 63 | 0.560 |
Why?
| | Immune Tolerance | 1 | 2018 | 329 | 0.550 |
Why?
| | Respiratory System | 1 | 2017 | 140 | 0.550 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 220 | 0.550 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 243 | 0.530 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 15 | 0.530 |
Why?
| | Mice, Inbred C57BL | 8 | 2024 | 4770 | 0.530 |
Why?
| | Male | 23 | 2023 | 55796 | 0.530 |
Why?
| | Milk, Human | 1 | 2017 | 132 | 0.520 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 161 | 0.520 |
Why?
| | Fetal Diseases | 1 | 2016 | 145 | 0.500 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 69 | 0.500 |
Why?
| | Nitric Oxide | 3 | 2019 | 830 | 0.490 |
Why?
| | Sex Characteristics | 1 | 2019 | 642 | 0.490 |
Why?
| | Child Advocacy | 2 | 2005 | 32 | 0.490 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2014 | 72 | 0.470 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 559 | 0.470 |
Why?
| | Infant | 9 | 2023 | 7955 | 0.470 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 52 | 0.470 |
Why?
| | Calcium | 1 | 2020 | 1107 | 0.470 |
Why?
| | Intestinal Atresia | 1 | 2014 | 15 | 0.470 |
Why?
| | Endothelin-1 | 1 | 2015 | 166 | 0.460 |
Why?
| | Visual Perception | 1 | 2015 | 139 | 0.460 |
Why?
| | Resuscitation | 1 | 2016 | 215 | 0.450 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 38 | 0.450 |
Why?
| | Gestational Age | 3 | 2022 | 753 | 0.450 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 65 | 0.440 |
Why?
| | Fibroblasts | 3 | 2015 | 836 | 0.440 |
Why?
| | Intestine, Small | 1 | 2014 | 128 | 0.430 |
Why?
| | Pediatrics | 3 | 2005 | 968 | 0.430 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 179 | 0.430 |
Why?
| | Hepatocytes | 3 | 2024 | 200 | 0.420 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1217 | 0.420 |
Why?
| | Female | 21 | 2023 | 59773 | 0.410 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 176 | 0.410 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 104 | 0.410 |
Why?
| | Clinical Competence | 1 | 2019 | 912 | 0.410 |
Why?
| | Phospholipids | 1 | 2013 | 201 | 0.400 |
Why?
| | Colon | 1 | 2014 | 234 | 0.400 |
Why?
| | Respiration Disorders | 1 | 2012 | 66 | 0.400 |
Why?
| | Urinary Bladder | 1 | 2014 | 166 | 0.400 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 924 | 0.370 |
Why?
| | Patient Safety | 1 | 2013 | 274 | 0.360 |
Why?
| | Microcirculation | 1 | 2010 | 136 | 0.360 |
Why?
| | Glycolysis | 2 | 2021 | 222 | 0.360 |
Why?
| | Body Mass Index | 1 | 2017 | 1989 | 0.350 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 156 | 0.350 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 41 | 0.340 |
Why?
| | Cells, Cultured | 5 | 2019 | 3879 | 0.340 |
Why?
| | Cell Line | 4 | 2017 | 2628 | 0.330 |
Why?
| | Curriculum | 2 | 2005 | 853 | 0.320 |
Why?
| | Hydrocortisone | 2 | 2020 | 262 | 0.320 |
Why?
| | Cognition | 1 | 2015 | 980 | 0.300 |
Why?
| | Cytokines | 3 | 2023 | 1837 | 0.290 |
Why?
| | Biomarkers | 2 | 2017 | 3450 | 0.290 |
Why?
| | Interleukin-6 | 2 | 2022 | 668 | 0.280 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 827 | 0.280 |
Why?
| | Gene Silencing | 2 | 2021 | 176 | 0.270 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2018 | 117 | 0.270 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 148 | 0.260 |
Why?
| | Indomethacin | 2 | 2023 | 74 | 0.260 |
Why?
| | Endothelial Cells | 1 | 2010 | 685 | 0.260 |
Why?
| | Internship and Residency | 2 | 2005 | 948 | 0.260 |
Why?
| | Biological Evolution | 1 | 2009 | 416 | 0.260 |
Why?
| | History, 20th Century | 2 | 2017 | 276 | 0.260 |
Why?
| | Cell Survival | 3 | 2021 | 1011 | 0.250 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 798 | 0.250 |
Why?
| | Patient Advocacy | 1 | 2005 | 66 | 0.240 |
Why?
| | Cell Nucleus | 2 | 2019 | 552 | 0.240 |
Why?
| | Mice, Knockout | 2 | 2021 | 2607 | 0.240 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 62 | 0.230 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 12 | 0.220 |
Why?
| | Zymosan | 1 | 2023 | 63 | 0.220 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 41 | 0.220 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 86 | 0.210 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 124 | 0.210 |
Why?
| | Age Factors | 2 | 2020 | 2908 | 0.210 |
Why?
| | RNA, Messenger | 3 | 2019 | 2579 | 0.200 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 166 | 0.200 |
Why?
| | Ligation | 1 | 2022 | 77 | 0.200 |
Why?
| | Morbidity | 2 | 2021 | 279 | 0.200 |
Why?
| | Dyspnea | 1 | 2023 | 223 | 0.200 |
Why?
| | Hepatic Veins | 1 | 2021 | 31 | 0.200 |
Why?
| | Dilatation | 1 | 2022 | 58 | 0.200 |
Why?
| | Transcription Factors | 1 | 2009 | 1531 | 0.190 |
Why?
| | Insulinoma | 1 | 2021 | 29 | 0.190 |
Why?
| | Fetal Blood | 1 | 2023 | 268 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 37 | 0.190 |
Why?
| | Vascular Malformations | 1 | 2021 | 47 | 0.190 |
Why?
| | C-Reactive Protein | 1 | 2023 | 359 | 0.190 |
Why?
| | Portal Vein | 1 | 2021 | 85 | 0.190 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 42 | 0.190 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 6 | 0.190 |
Why?
| | Selenium | 1 | 2020 | 31 | 0.190 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 15 | 0.190 |
Why?
| | Ventilator Weaning | 1 | 2020 | 33 | 0.180 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 154 | 0.180 |
Why?
| | Homeostasis | 1 | 2024 | 579 | 0.180 |
Why?
| | Chelating Agents | 1 | 2020 | 67 | 0.180 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 59 | 0.180 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 169 | 0.170 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 9 | 0.170 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 136 | 0.170 |
Why?
| | Primary Cell Culture | 1 | 2020 | 147 | 0.170 |
Why?
| | Proteolysis | 1 | 2020 | 145 | 0.170 |
Why?
| | Norepinephrine | 1 | 2020 | 205 | 0.170 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 301 | 0.170 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 94 | 0.170 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 65 | 0.170 |
Why?
| | Spleen | 1 | 2020 | 486 | 0.160 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 17 | 0.160 |
Why?
| | Weight Gain | 2 | 2023 | 463 | 0.160 |
Why?
| | Cytosol | 1 | 2019 | 205 | 0.160 |
Why?
| | Consensus | 1 | 2021 | 531 | 0.160 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 62 | 0.160 |
Why?
| | Morphogenesis | 1 | 2019 | 161 | 0.160 |
Why?
| | Delivery Rooms | 1 | 2018 | 6 | 0.160 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 29 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 19 | 0.150 |
Why?
| | Rotation | 1 | 2018 | 113 | 0.150 |
Why?
| | Protective Agents | 1 | 2018 | 38 | 0.150 |
Why?
| | Sheep | 1 | 2020 | 763 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1758 | 0.150 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 67 | 0.150 |
Why?
| | Overnutrition | 1 | 2017 | 33 | 0.150 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 145 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2019 | 209 | 0.140 |
Why?
| | Pennsylvania | 1 | 2017 | 94 | 0.140 |
Why?
| | Parturition | 1 | 2017 | 54 | 0.140 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 67 | 0.140 |
Why?
| | Conservative Treatment | 1 | 2017 | 29 | 0.140 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 68 | 0.140 |
Why?
| | Calibration | 1 | 2017 | 129 | 0.140 |
Why?
| | Time-to-Treatment | 1 | 2018 | 146 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2018 | 322 | 0.140 |
Why?
| | Protective Factors | 1 | 2016 | 87 | 0.140 |
Why?
| | History, 21st Century | 1 | 2017 | 164 | 0.140 |
Why?
| | Primary Prevention | 1 | 2018 | 171 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2018 | 148 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 546 | 0.140 |
Why?
| | Up-Regulation | 1 | 2019 | 818 | 0.130 |
Why?
| | Precision Medicine | 1 | 2019 | 352 | 0.130 |
Why?
| | Macaca mulatta | 1 | 2016 | 129 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2011 | 2197 | 0.130 |
Why?
| | Cholestasis | 1 | 2018 | 224 | 0.130 |
Why?
| | Administration, Oral | 1 | 2017 | 735 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2017 | 181 | 0.120 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.120 |
Why?
| | Body Composition | 1 | 2018 | 591 | 0.120 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 7 | 0.120 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 2756 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.120 |
Why?
| | Pilot Projects | 1 | 2018 | 1355 | 0.110 |
Why?
| | Kidney | 1 | 2020 | 1203 | 0.110 |
Why?
| | Child | 4 | 2018 | 18435 | 0.110 |
Why?
| | Breast Feeding | 1 | 2017 | 371 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 745 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1393 | 0.110 |
Why?
| | Interleukins | 1 | 2015 | 236 | 0.110 |
Why?
| | Adult | 4 | 2023 | 30576 | 0.110 |
Why?
| | Syndrome | 1 | 2014 | 337 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1805 | 0.110 |
Why?
| | Software | 1 | 2017 | 533 | 0.110 |
Why?
| | Brain Injuries | 1 | 2017 | 448 | 0.110 |
Why?
| | Rats | 2 | 2013 | 5033 | 0.110 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 286 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 2988 | 0.100 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 40 | 0.100 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 111 | 0.100 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 47 | 0.100 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 130 | 0.100 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 273 | 0.100 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 15 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2440 | 0.100 |
Why?
| | Radiography | 1 | 2014 | 825 | 0.100 |
Why?
| | Cohort Studies | 2 | 2019 | 4960 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 331 | 0.090 |
Why?
| | Circadian Rhythm | 1 | 2014 | 371 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2015 | 1973 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2088 | 0.090 |
Why?
| | Protoporphyrins | 1 | 2009 | 16 | 0.090 |
Why?
| | Caspase 3 | 1 | 2010 | 234 | 0.090 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 47 | 0.090 |
Why?
| | Cyclin D1 | 1 | 2009 | 60 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1344 | 0.090 |
Why?
| | Child, Preschool | 2 | 2018 | 9124 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 528 | 0.080 |
Why?
| | Blood Glucose | 1 | 2018 | 1819 | 0.080 |
Why?
| | Luciferases | 1 | 2008 | 136 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 373 | 0.080 |
Why?
| | Genes, Reporter | 1 | 2008 | 259 | 0.080 |
Why?
| | Tyrosine | 1 | 2008 | 214 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 130 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1567 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 271 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 348 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2251 | 0.080 |
Why?
| | Aging | 1 | 2017 | 1636 | 0.080 |
Why?
| | Risk Factors | 2 | 2019 | 8684 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 858 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 749 | 0.070 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1241 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 1710 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2104 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 91 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1569 | 0.060 |
Why?
| | United States | 2 | 2013 | 12310 | 0.060 |
Why?
| | Program Development | 1 | 2005 | 346 | 0.050 |
Why?
| | Educational Measurement | 1 | 2005 | 261 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 244 | 0.050 |
Why?
| | Child Health Services | 1 | 2004 | 174 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1352 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 636 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1642 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 378 | 0.050 |
Why?
| | Fetal Development | 1 | 2023 | 248 | 0.050 |
Why?
| | Program Evaluation | 1 | 2005 | 828 | 0.050 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 15 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 902 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 18 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 36 | 0.040 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.040 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 30 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 640 | 0.040 |
Why?
| | Caspase 1 | 1 | 2018 | 141 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 114 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2019 | 136 | 0.040 |
Why?
| | Lipoproteins | 1 | 2018 | 160 | 0.040 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 93 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 227 | 0.040 |
Why?
| | Caspases | 1 | 2018 | 244 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 277 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 196 | 0.030 |
Why?
| | Bleomycin | 1 | 2018 | 232 | 0.030 |
Why?
| | Comet Assay | 1 | 2014 | 15 | 0.030 |
Why?
| | DNA Damage | 1 | 2014 | 348 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 55 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 53 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 107 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1187 | 0.020 |
Why?
| | Injections | 1 | 2011 | 161 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 325 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 23 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 31 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 61 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 72 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 82 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 153 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 281 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 776 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 757 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1164 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 936 | 0.020 |
Why?
| | Time Factors | 1 | 2011 | 6133 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|